Clinical significance of glycated hemoglobin in the acute phase of ST elevation myocardial infarction.
In population-based studies, including diabetic and nondiabetic cohorts, glycated hemoglobin A1c (HbA1c) has been reported as an independent predictor of all-cause and cardiovascular disease mortality. Data on the prognostic role of HbA1c in patients with acute myocardial infarction (MI) are not univocal since they stem from studies which mainly differ in patients' selection criteria, therapy (thrombolysis vs mechanical revascularization) and number consistency. The present review is focused on available evidence on the prognostic significance of HbA1c measured in the acute phase in patients with ST-elevation myocardial infarction (STEMI) submitted to primary percutaneous coronary intervention (PCI). We furthermore highlighted the role of HbA1c as a screening tool for glucose intolerance in patients with STEMI. According to available evidence, in contemporary cohorts of STEMI patients submitted to mechanical revascularization, HbA1c does not seem to be associated with short and long term mortality rates. However, HbA1c may represent a screening tool for glucose intolerance from the early phase on in STEMI patients. On a pragmatic ground, an HbA1c test has several advantages over fasting plasma glucose or an oral glucose tolerance test in an acute setting. The test can be performed in the non-fasting state and reflects average glucose concentration over the preceding 2-3 mo. We therefore proposed an algorithm based on pragmatic grounds which could be applied in STEMI patients without known diabetes in order to detect glucose intolerance abnormalities from the early phase. The main advantage of this algorithm is that it may help in tailoring the follow-up program, by helping in identifying patients at risk for the development of glucose intolerance after MI. Further validation of this algorithm in prospective studies may be required in the contemporary STEMI population to resolve some of these uncertainties around HbA1c screening cutoff points.
Chiara Lazzeri, Serafina Valente, Marco Chiostri, Maria Grazia D'Alfonso, Gian Franco Gensini, Intensive Cardiac Care Unit, Heart and Vessel Department, Azienda Ospedaliero, Universitaria Careggi, 50134 Florence, Italy.
Chiara
C
Lazzeri
Chiara Lazzeri, Serafina Valente, Marco Chiostri, Maria Grazia D'Alfonso, Gian Franco Gensini, Intensive Cardiac Care Unit, Heart and Vessel Department, Azienda Ospedaliero, Universitaria Careggi, 50134 Florence, Italy.
Serafina
S
Valente
Chiara Lazzeri, Serafina Valente, Marco Chiostri, Maria Grazia D'Alfonso, Gian Franco Gensini, Intensive Cardiac Care Unit, Heart and Vessel Department, Azienda Ospedaliero, Universitaria Careggi, 50134 Florence, Italy.
Marco
M
Chiostri
Chiara Lazzeri, Serafina Valente, Marco Chiostri, Maria Grazia D'Alfonso, Gian Franco Gensini, Intensive Cardiac Care Unit, Heart and Vessel Department, Azienda Ospedaliero, Universitaria Careggi, 50134 Florence, Italy.
Maria Grazia
MG
D'Alfonso
Chiara Lazzeri, Serafina Valente, Marco Chiostri, Maria Grazia D'Alfonso, Gian Franco Gensini, Intensive Cardiac Care Unit, Heart and Vessel Department, Azienda Ospedaliero, Universitaria Careggi, 50134 Florence, Italy.
Gian Franco
GF
Gensini
Glucose intolerance; Glycated hemoglobin; Hyperglycemia; Prognosis; ST-elevation myocardial infarction